Skip to content
Advertisement

SOPHiA GENETICS’ SOPHiA DDM platform has analyzed more than 1.8 million genomic profiles submitted by a global network of hospital, laboratory, and biopharma partners, applying machine learning to call and classify variants from raw sequencing data. SOPHiA GENETICS is publicly traded (Nasdaq: SOPH).

Tabular
Advertisement